Optimizing Therapy for Infections Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases

ABSTRACT

The spread of multidrug-resistant Enterobacteriaceae is complicating the treatment of nosocomial infections. In many parts of the world, resistance to third-generation cephalosporins exceeds 10% of total nosocomial isolates and 30% of isolates detected in the intensive care unit. This resistance is frequently due to the acquisition of plasmids containing genes encoding for extended-spectrum β-lactamases (ESBLs). Furthermore, these mobile elements often carry genes encoding resistance to other drugs such as aminoglycosides. A high risk of poor clinical outcome has been observed in patients infected with ESBL producers receiving third-generation cephalosporins, even if the organism appears susceptible to the antibiotic. For this reason, clinical microbiology laboratories are advised to incorporate specific ESBL detection methodology into routine clinical practice. This should prevent erroneous use of cephalosporins for these infections. Most ESBL producers remain susceptible to carbapenems, and these agents are considered the drugs of choice against ESBL-producing organisms. Unfortunately, there is now an increasing occurrence of carbapenem resistance in the Enterobacteriaceae. In this context, clinical response to new antibiotics (e.g., tigecycline) and old antibiotics (e.g., colistin) with good in vitro activity against ESBL producers needs to be evaluated.

KEYWORDS

β-lactams - ICU - epidemiology - outcome - therapy

REFERENCES

• 1 Eisenstein B I, Zaleznik D F. Enterobacteriaceae. In: Mandell GL, Bennett JE, Dolin RD Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA; Churchill Livingstone 2000: 2294-2309
• 2 Jones M E, Draghi D C, Thornsberry C, Karlowsky J A, Sahm D F, Wenzel R P. Emerging resistance among bacterial pathogens in the intensive care units-a European and North American surveillance study (2000-2002).  Ann Clin Microbiol Antimicrob. 2004;  3 14
• 3 Gaynes R, Edwards J R. and National Nosocomial Infections Surveillance System . Overview of nosocomial infections caused by gram-negative bacilli.  Clin Infect Dis. 2005;  41 848-854
• 4 Paterson D L, Bonomo R A. Extended-spectrum β-lactamases: a clinical update.  Clin Microbiol Rev. 2005;  18 657-686
• 5 Queenan A M, Bush K. Carbapenemases: the versatile beta-lactamases.  Clin Microbiol Rev. 2007;  20 440-458
• 6 Cantón R, Coque T M. The CTX-M β-lactamases pandemic.  Curr Opin Microbiol. 2006;  9 466-475
• 7 Hanson N D. AmpC beta-lactamases: what do we need to know for the future?.  J Antimicrob Chemother. 2003;  52 2-4
• 8 Clinical and Laboratory Standard Methods .Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. CLSI document M100-S16. Wayne, PA; Clinical and Laboratory Standards Institute 2006
• 9 Paterson D L, Ko W C, Von Gottberg A et al.. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory.  J Clin Microbiol. 2001;  39 2206-2212
• 10 Paterson D L, Ko W C, Von Gottberg A et al.. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases.  Clin Infect Dis. 2004;  39 31-37
• 11 Rodriguez-Bano J, Navarro M D, Romero L et al.. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.  Clin Infect Dis. 2006;  43 1407-1414
• 12 Kang C I, Kim S H, Park W B et al.. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.  Antimicrob Agents Chemother. 2004;  48 4574-4581
• 13 Endimiani A, Luzzaro F, Brigante G et al.. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.  Antimicrob Agents Chemother. 2005;  49 2598-2605
• 14 Wong-Beringer A, Hindler J, Loeloff M et al.. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.  Clin Infect Dis. 2002;  34 135-146
• 15 Schiappa D A, Hayden M K, Matushek M G et al.. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case control and molecular epidemiologic investigation.  J Infect Dis. 1996;  174 529-536
• 16 Du B, Long Y, Liu H et al.. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.  Intensive Care Med. 2002;  28 1718-1723
• 17 Kim B N, Woo J H, Kim M N, Ryu J, Kim Y S. Clinical implications of extended-spectrum β-lactamases-producing Klebsiella pneumoniae bacteraemia.  J Hosp Infect. 2002;  52 99-106
• 18 Bhavnani S M, Ambrose P G, Craig W A, Dudley M N, Jones R N. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella pneumoniae species as defined by CLSI reference methods: report from the SENTRY antimicrobial surveillance program.  Diagn Microbiol Infect Dis. 2006;  54 231-236
• 19 Tumbarello M, Spanu T, Sanguinetti M et al.. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.  Antimicrob Agents Chemother. 2006;  50 498-504
• 20 Ariffin H, Navaratnam P, Mohamed M et al.. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia.  Int J Infect Dis. 2000;  4 21-25
• 21 Lautenbach E, Patel J B, Bilker W B, Edelstein P H, Fishman N O. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.  Clin Infect Dis. 2001;  32 1162-1171
• 22 Ho P L, Chan W M, Tsang K W, Wong S S, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes.  Scand J Infect Dis. 2002;  34 567-573
• 23 Kim Y K, Pai H, Lee H J et al.. Bloodstream infection by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.  Antimicrob Agents Chemother. 2002;  46 1481-1491
• 24 Marra A R, Wey S B, Castelo A et al.. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.  BMC Infect Dis. 2006;  6 24
• 25 Lee S Y, Kotapati S, Kuti J L, Nightingale C H, Nicolau D P. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.  Infect Control Hosp Epidemiol. 2006;  27 1226-1232
• 26 Schwaber M J, Navon-Venezia S, Kaye K S, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae .  Antimicrob Agents Chemother. 2006;  50 1257-1262
• 27 Sader H S, Hsiung A, Fritsche T R, Jones R N. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.  Diagn Microbiol Infect Dis. 2007;  57 341-344
• 28 Goossens H, Grabein B. Prevalence of antimicrobial susceptibility data for extended-spectrum β-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and United States (1997-2004).  Diagn Microbiol Infect Dis. 2005;  53 257-264
• 29 Meyer K S, Urban C, Eagan J A, Berger B J, Rahal J J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins.  Ann Intern Med. 1993;  119 353-358
• 30 Endimiani A, Luzzaro F, Perilli M et al.. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin.  Clin Infect Dis. 2004;  38 243-251
• 31 Huang S S, Lee M H, Leu H S. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella .  J Microbiol Immunol Infect. 2006;  39 496-502
• 32 Munoz L S, Hovsepian M, Snydman D R et al.. Ertapenem for the treatment of extended-spectrum β-lactamase (ESBL) producing organisms. Abstract K-1591, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, Oct 30-Nov 2 Washington, DC;
• 33 Bratu S, Landman D, Haag R et al.. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.  Arch Intern Med. 2005;  165 1430-1435
• 34 Yu W L, Pfaller M A, Winokur P L, Jones R N. Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan.  Emerg Infect Dis. 2002;  8 522-524
• 35 Brigante G, Luzzaro F, Perilli M et al.. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients.  Int J Antimicrob Agents. 2005;  25 157-162
• 36 Zanetti G, Bally F, Greub G et al.. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.  Antimicrob Agents Chemother. 2003;  11 3442-3447
• 37 Kotapati S, Kuti J, Nightingale C H, Nicolau D P. Clinical implications of extended-spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.  J Infect. 2005;  51 211-217
• 38 LaBombardi V J, Rojtman A, Tran K. Use of cefepime for the treatment of infections caused by extended-spectrum β-lactamases-producing Klebsiella pneumoniae and Escherichia coli .  Diagn Microbiol Infect Dis. 2006;  56 313-315
• 39 Goethaert K, Van Looveren M, Lammens C et al.. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.  Clin Microbiol Infect. 2006;  12 56-62
• 40 Luzzaro F, Mezzatesta M, Mugnaioli C et al.. Trends in production of extended-spectrum β-lactamases among enterobacteria of medical interest: report from the second Italian nationwide survey.  J Clin Microbiol. 2006;  44 1659-1664
• 41 Rice L B, Carias L L, Hujer A M et al.. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae .  Antimicrob Agents Chemother. 2000;  44 362-367
• 42 Ambrose P G, Bhavnani S M, Jones R N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program.  Antimicrob Agents Chemother. 2003;  47 1643-1646
• 43 Bhavnani S M, Ambrose P G, Craig W A, Dudley M N, Jones R N. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella pneumoniae species as defined by CLSI reference methods: report from the SENTRY antimicrobial surveillance program.  Diagn Microbiol Infect Dis. 2006;  54 231-236
• 44 Gavin P J, Suseno M T, Thomson Jr R B et al.. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.  Antimicrob Agents Chemother. 2006;  50 2244-2247
• 45 Burgess D S, Hall II R G, Lewis II J S, Jorgensen J H, Patterson J E. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.  Pharmacotherapy. 2003;  23 1232-1237
• 46 Pillay T, Pillay D G, Adhikari M, Sturm A W. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.  Am J Perinatol. 1998;  15 47-51
• 47 Paterson D L, Singh N, Gayowski T, Marino I R. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.  Clin Infect Dis. 1999;  28 683-684
• 48 Zimhony O, Chmelnitsky I, Bardenstein R et al.. Endocarditis caused by extended-spectrum beta-lactamase producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.  Antimicrob Agents Chemother. 2006;  50 3179-3182
• 49 Pangon B, Bizet C, Bure A et al.. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase.  J Infect Dis. 1989;  159 1005-1006
• 50 Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomas J M, Benedi V J, Jacoby G A. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins.  Antimicrob Agents Chemother. 1996;  40 342-348
• 51 Bradford P A, Urban C, Mariano N, Projan S J, Rahal J J, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein.  Antimicrob Agents Chemother. 1997;  41 563-569
• 52 Lee C H, Su L H, Tang Y F, Liu J W. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.  J Antimicrob Chemother. 2006;  58 1074-1077
• 53 Paterson D L, Mulazimoglu L, Casellas J M et al.. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.  Clin Infect Dis. 2000;  30 473-478
• 54 Pattharachayakul S, Neuhauser M M, Quinn J P, Pendland S L. Extended-spectrum beta-lactamase producing Klebsiella pneumoniae: activity of single versus combination agents.  J Antimicrob Chemother. 2003;  51 737-739
• 55 Livermore D M. Tigecycline: what is it, and where should it be used?.  J Antimicrob Chemother. 2005;  56 611-614
• 56 Morosini M I, Garcia-Castillo M, Coque T M et al.. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.  Antimicrob Agents Chemother. 2006;  50 2695-2699
• 57 Hope R, Warner M, Potz N A, Fagan E J, James D, Livermore D M. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.  J Antimicrob Chemother. 2006;  58 1312-1314
• 58 Biedenbach D J, Beach M L, Jones R N. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.  Diagn Microbiol Infect Dis. 2001;  40 173-177
• 59 Peleg A Y, Potoski B A, Rea R et al.. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.  J Antimicrob Chemother. 2007;  59 128-131
• 60 Li J, Nation R L, Turnidge J D et al.. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections.  Lancet Infect Dis. 2006;  6 589-601
• 61 de Cueto M, Lopez L, Hernandez J R, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.  Antimicrob Agents Chemother. 2006;  50 368-370